Search results for "Criteri"

showing 10 items of 807 documents

Role of Densitometric Criteria in Evaluation of Effectiveness of Antiangiogenic Therapies in Metastatic Colorectal Cancer: An Italian Clinical Experi…

2017

Background/Aim: To evaluate the role of densitometric criterion using the Choi Criteria in the assessment of the response to antiangiogenic treatments of metastatic colorectal cancer (mCRC) compared to the RECIST criteria. Patients and Methods: Fifty-four patients (mean age=50.6 years ) affected by advanced colorectal cancer and with hepatic and possibly peritoneal and pulmonary metastases, that can be treated with bevacizumab, were prospectively evaluated by computerized tomography (CT) scan. Metastases were also evaluated by CT in onedimensional form according to RECIST. Results: Results show that in 58% of analyzed cases, stable disease according to RECIST coincided with stable disease a…

OncologyMalemedicine.medical_specialtyCancer ResearchBevacizumabDensitometric criteriaColorectal cancerAntiangiogenic therapyAngiogenesis InhibitorsColorectal NeoplasmAdvanced colorectal cancerStable DiseaseChoi CriteriaInternal medicinePartial responseMultidetector Computed TomographymedicineHumansDemographybusiness.industryDisease progressionLiver NeoplasmsMean ageGeneral MedicineMiddle Agedmedicine.diseaseTreatment OutcomeRECISTOncologyItalyLiver NeoplasmCHOIFemaleMetastatic colorectal cancer (mCRC)businessColorectal Neoplasmsmedicine.drugAngiogenesis InhibitorHumanDensitometryAnticancer research
researchProduct

Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patie…

2020

Prognosticating outcomes in liver transplant (LT) for hepatocellular carcinoma (HCC) continues to challenge the field. Although Milan Criteria (MC) generalized the practice of LT for HCC and improved outcomes, its predictive character has degraded with increasing candidate and oncological heterogeneity. We sought to validate and recalibrate a previously developed, preoperatively calculated, continuous risk score, the Hazard Associated with Liver Transplantation for Hepatocellular Carcinoma (HALTHCC), in an international cohort. From 2002 to 2014, 4,089 patients (both MC in and out [25.2%]) across 16 centers in North America, Europe, and Asia were included. A continuous risk score using pre-…

OncologyMalemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/18 - CHIRURGIA GENERALEmedicine.medical_treatmentInternational CooperationPROGNOSTIC SCORETumor burdengastroenterologyLIVER TRANSPLANTATION HEPATOCELLULAR CARCINOMA RISK FACTORS OUTCOME PROGNOSTIC SCORELiver transplantationMilan criteriaRisk AssessmentLiver diseaseInternal medicinemedicineHumansHepatology; gastroenterology; hepatocelluar cancer; locoregional therapiesHEPATOCELLULAR CARCINOMARetrospective StudiesOUTCOMEFramingham Risk ScoreHepatologybusiness.industryPoorly differentiatedLiver Neoplasmshepatocelluar cancerMiddle Agedmedicine.diseasePrognosisSettore MED/18Liver TransplantationRISK FACTORSHepatocellular carcinomaCohortlocoregional therapiesFemalebusinessHepatology (Baltimore, Md.)References
researchProduct

Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodie…

2021

Background: Metastatic colorectal cancer (mCRC) with wild type expression of RAS and RAF genes can be treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, such as cetuximab, in combination with chemotherapy. Skin toxicity represents the most serious and frequent side effect in these patients. Skin manifestations occur in approximately 80% of patients. In this study, we investigated the consequences on body image and quality of life (QoL) of patients with severe skin toxicity. Methods: One hundred patients were enrolled with mCRC. All patients signed informed consent and completed questionnaires to assess QoL and body discomfort. Toxicity was assessed on Common Te…

OncologyQuality of lifeCancer Researchmedicine.medical_specialtySide effectColorectal cancermedicine.medical_treatmentPsychological reactionsCetuximabMetastasesQuality of lifeInternal medicinemedicineChemotherapyChemotherapySkin rashCetuximabintegumentary systembusiness.industryMetastatic colorectal carcinomaCommon Terminology Criteria for Adverse Eventsmedicine.diseaseRashhumanitiesOncologyToxicityOriginal Articlemedicine.symptombusinessmedicine.drugWorld journal of oncology
researchProduct

Alpha-fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular ca…

2013

Locoregional therapy (LRT) is being increasingly used for the management of hepatocellular cancer (HCC) in patients listed for liver transplantation (LT). Although several selection criteria have been developed, stratifications of survival according to the pathology of explanted livers and pre-LT LRT are lacking. Radiological progression according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) and alpha-fetoprotein (AFP) behavior was reviewed for 306 patients within the Milan criteria (MC-IN) and 116 patients outside the Milan criteria (MC-OUT) who underwent LRT and LT between January 1999 and March 2010. A prospectively collected database originating from 6 collabor…

OncologyTransplantationmedicine.medical_specialtyHepatologybusiness.industrymedicine.medical_treatmentMilan criteriaLiver transplantationmedicine.diseaseSurgeryTransplantationResponse Evaluation Criteria in Solid TumorsTumor progressionInternal medicineCarcinomaMedicineSurgeryRisk factorbusinessProspective cohort studyLiver Transplantation
researchProduct

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

2018

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein. (C) 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Oncologymedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentMilan criteriaLiver transplantation03 medical and health sciences0302 clinical medicineResectable Hepatocellular CarcinomaHepatocellular carcinomaliver transplantation radiofrequenza ablation contrast enhanced Ultrasound antiangiogenetic drugs immunotherapyInternal medicinemedicineHumansEarly Hepatocellular CarcinomaSocieties MedicalHepatologybusiness.industryLiver NeoplasmsGastroenterologyDisease ManagementCancermedicine.diseaseBCLC Stage3. Good healthEurope030220 oncology & carcinogenesisHepatocellular carcinomaPractice Guidelines as Topic030211 gastroenterology & hepatologyLiver cancerbusinessJournal of Hepatology
researchProduct

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

2015

Abstract Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are hematologically diverse stem cell malignancies sharing phenotypic features of both myelodysplastic syndromes and myeloproliferative neoplasms. There are currently no standard treatment recommendations for most adult patients with MDS/MPN. To optimize efforts to improve the management and disease outcomes, it is essential to identify meaningful clinical and biologic end points and standardized response criteria for clinical trials. The dual dysplastic and proliferative features in these stem cell malignancies define their uniqueness and challenges. We propose response assessment guidelines to harmonize future…

Oncologymedicine.medical_specialtyInternational CooperationImmunologyMEDLINEMedical OncologyBiochemistryMyeloproliferative DisordersSurveys and QuestionnairesInternal medicinehemic and lymphatic diseasesmedicineHumansResponse criteriaCell ProliferationClinical Trials as TopicMyeloproliferative DisordersAdult patientsSurrogate endpointbusiness.industryStandard treatmentMyelodysplastic syndromesfood and beveragesCell BiologyHematologymedicine.diseaseClinical trialPhenotypeTreatment OutcomeHematologic NeoplasmsMyelodysplastic SyndromesMutationPractice Guidelines as TopicDisease ProgressionPhysical therapybusinessAlgorithmsPerspectives
researchProduct

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Int…

2011

The Gynecological Cancer Intergroup (GCIG) has previously reached consensus regarding the criteria that should be used in clinical trial protocols to define progression-free survival after first-line therapy as well as the criteria to define response to treatment in recurrent disease using the serum marker CA 125 and has specified the situations where these criteria should be used. However, the publications did not include detailed definitions, nor were they written to accommodate the new version of Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.1) now available. Thus, we recommend that the definitions described later in detail are incorporated into clinical trial…

Oncologymedicine.medical_specialtyMEDLINEAntineoplastic AgentsDisease-Free SurvivalInternal medicinemedicineRecurrent diseaseHumansIn patientOvarian NeoplasmsClinical Trials as Topicbusiness.industryObstetrics and Gynecologymedicine.diseaseGynecological cancerResponse to treatmentSurgeryClinical trialOncologyResponse Evaluation Criteria in Solid TumorsCA-125 AntigenDisease ProgressionFemaleHuman medicineNeoplasm Recurrence LocalOvarian cancerbusiness
researchProduct

Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or me…

2019

Oncologymedicine.medical_specialtyTemozolomideSurrogate endpointbusiness.industryCancerHematologyNeutropeniamedicine.diseaseChemotherapy regimenPoly (ADP-Ribose) Polymerase Inhibitorchemistry.chemical_compoundOncologychemistryResponse Evaluation Criteria in Solid TumorsInternal medicinemedicineRucaparibbusinessmedicine.drugAnnals of Oncology
researchProduct

An academic performance indicator using flexible multi-criteria methods

2021

Composite indicators are a very useful tool for conveying summary information on the overall performance of institutions and facilitating decision-making. Increasingly, there is a demand for indicators that allow performance to be assessed after the implementation of a strategy. This has several difficulties, and in this paper, we address three of them: how to evaluate at different points in time, how to estimate the weighting of the criteria and how to normalize the data. Our proposal is based on multicriteria techniques, using a recent method, uwTOPSIS, and is applied to data collected from 2975 students enrolled in the first year of science and engineering at the Industrial University of…

Operations researchComputer scienceGeneral MathematicsData management:CIENCIAS ECONÓMICAS [UNESCO]Computer Science (miscellaneous)QA1-939TOPSISEngineering (miscellaneous)MCDMcomputer.programming_languageMeasure (data warehouse)business.industryuwTOPSISR Programming LanguageTOPSISUNESCO::CIENCIAS ECONÓMICASPython (programming language)topsisMultiple-criteria decision analysismcdmWeightinguwtopsisacademic performance indicatorPerformance indicatorbusinesscomputercomposite indicatorsMathematics
researchProduct

Multi‐criteria decision‐making approach for modular enterprise resource planning sorting problems

2021

[EN] Implementing Enterprise Resource Planning (ERP) systems is currently recognized as a best practice with wide associated possibilities of business improvement for companies. Integrating these kinds of systems with business processes in the most efficient way requires to endeavour as much as possible simplifications for final users, which can be pursued by optimizing crucial software characteristics. The present article proposes a novel Multi-Criteria Decision-Making (MCDM) approach to deal with such an issue. Specifically, the ELECTRE (ELimination Et Choix Traduisant la REalite) TRI technique is suggested to assign ERP modules into predefined and ordered categories according to maintain…

Operations researchComputer sciencebusiness.industryStrategy and ManagementUsabilityMaintainabilitySortingGeneral Decision SciencesUsabilityModular designMultiple-criteria decision analysisMulti criteria decisionEnterprise resource planningMaintainabilityELECTRE TRIMATEMATICA APLICADAbusinessEnterprise resource planningMCDMJournal of Multi-Criteria Decision Analysis
researchProduct